Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Phase III clinical trials in chemotherapy-naive patients with advanced NSCLC assessing the combination of atezolizumab and chemotherapy

Date

08 Oct 2016

Session

Poster Display

Presenters

Martin Reck

Citation

Annals of Oncology (2016) 27 (6): 416-454. 10.1093/annonc/mdw383

Authors

M. Reck1, V.A. Papadimitrakopoulou2, F. Cappuzzo3, R. Jotte4, T.S.K. Mok5, A. Sandler6, D. Waterkamp6, S. Coleman6, T. Asakawa6, M. Socinski7

Author affiliations

  • 1 Head Of Department Of Thoracic Oncology, Lung Clinic Grosshansdorf, 22927 - Grosshansdorf/DE
  • 2 Medical Oncology, MD Anderson Cancer Center, Houston/US
  • 3 U.o. Oncologia Medica, Ospedale Civile - Istituto Toscano Tumori, 57100 - Livorno/IT
  • 4 Oncology, Rocky Mountain Cancer Centers U.S. Oncology Network, Denver/US
  • 5 Oncology, Chinese University of Hong Kong, Hong Kong/HK
  • 6 Product Development Oncology, Genentech, Inc., South San Francisco/US
  • 7 Medical Oncology, University of Pittsburgh UPMC Cancer Pavilion, Pittsburgh/US
More

Resources

Abstract 2647

Background

Current treatments for advanced NSCLC include platinum (plat)-based doublet chemotherapy (chemo), pemetrexed (pem), bevacizumab, targeted drugs and programmed death-ligand 1 (PD-L1)/PD-1–targeted immunotherapy. Atezolizumab (atezo; anti-PDL1) inhibits binding of PD-L1 to PD-1 and B7.1 and restores anti-tumor T-cell activity. Clinical efficacy and survival rates with atezo monotherapy increase with increasing PD-L1 levels on tumor cells (TC) and tumor infiltrating immune cells (IC) in patients with advanced NSCLC. A phase Ib study revealed the potential for chemo to further enhance responses to atezo with tolerable safety in pts, across PD-L1 expression levels. The combination of atezo and chemo is now being examined in phase III studies.

Trial design

Three phase III randomized, multicenter, open-label studies are assessing plat-based chemo + atezo or plat-based chemo + atezo + pem as 1L therapy in chemo-naive pts with advanced NSCLC (Table). Pts will be enrolled regardless of PD-L1 status and must have previously untreated stage IV NSCLC. Inclusion criteria include measurable disease per RECIST v1.1 and ECOG PS 0-1; pts with untreated CNS metastases, autoimmune disease or prior immunotherapy will be excluded. Stratification factors will include sex and ECOG status. Archival tumor or biopsy sample will be obtained at screening. In IMpower130 and 131, pts will be randomized to receive atezo 1200 mg with standard plat-based chemotherapy for 4 or 6 21-day cycles, then maintenance with atezo. In IMpower132, pts will receive atezo 1200 mg q3w + plat-based chemo + pem, then maintenance with atezo + pem. Endpoints include OS, PFS, ORR, DOR, safety, PK and QOL. Tumor biopsies at RECIST v1.1 progression will be assessed to distinguish pseudoprogression/tumor-immune infiltration from actual progression and to evaluate biomarkers associated with response and immune escape.

Trial name Histology Planned enrollment Experimental arm Comparator arm Identifier
IMpower130 Non-squamous 650 Atezo + carboplatin+ nab-paclitaxel Carboplatin+ nab-paclitaxel NCT02367781
IMpower131 Squamous 1025 Atezo + carboplatin +  paclitaxel Atezo + carboplatin +  nab-paclitaxel Carboplatin+ nab-paclitaxel NCT02367794
IMpower132 Non-squamous 568 Atezo + carboplatin/ cisplatin+ pemetrexed Carboplatin/cisplatin+ pemetrexed NCT02657434

Clinical trial identification

IMpower130: NCT02367781 IMpower131: NCT02367794 IMpower132: NCT02657434

Legal entity responsible for the study

F. Hoffmann-La Roche Ltd.

Funding

F. Hoffmann-La Roche Ltd.

Disclosure

M. Reck: Consulting/advisory role and Speaker Bureau for Roche, Lilly, BMS, MSD, Astra Zeneca, Pfizer, Boehringer Ingeleim, Celgene. V.A. Papadimitrakopoulou: Consulting or advisory role with Genentech, Gensignis Life Sciences, Janssen, Clovis Oncology, Biothera, Merck. Research funding with Clovis, Astra Zeneca, Merck, Janssen, Bayer. F. Cappuzzo: Honoraria: Roche, Clovis, Pfizer. Consulting or Advisory: Roche, Clovis, Pfizer, Lilly. R. Jotte: Honoraria & Speakers Bureau: Eli Lilly, BMS. T.S.K. Mok: Leadership/stock: Sanomics, Honoraria/Consulting includes: AZ, Roche, Lily, Merck, MSD, BMS, BI, Novartis, Clovis, Amgen, Janssen, AVEO, Biodesix, Prime, ACEA Biosciences, Vertex, SFJ, GSK, Biomarin, Pfizer, vertex, SFS, ACFA, Biosciences, Genedecode. A. Sandler: Genentech employee, Compensated Consultant role for Genentech/Roche, Genentech/Roche stock, Honoraria recipient from Genentech/Roche, Genentech research funding paid to institution, Provided compensated expert testimony for Genentech/Roche. D. Waterkamp: Roche/Genentech employee. S. Coleman: Employment: Genentech Stock: Roche, Gilead Sciences, Celgene, Teva. T. Asakawa: Genentech employee. M. Socinski: Research support – Genentech Speaker's Bureau – Genentech.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings